Resoundant Appoints Joel Felmlee, PhD, as Chief Operating Officer
Rochester, MN, USA—Resoundant, Inc. is excited to announce the appointment of Joel Felmlee, PhD as the new Chief Operating Officer (COO)....
Apr 11, 20232 min read
Resoundant ships 2022nd MRE unit worldwide
Rochester, MN, USA—Resoundant, Inc. announced today that the company has shipped its 2022nd Magnetic Resonance Elastography (MRE) system...
Oct 31, 20223 min read
Exploring the use of MRE to guide treatment and predict outcomes in patients with NAFLD
Originally published by Mayo Clinic The ability to monitor disease progression in nonalcoholic fatty liver disease (NAFLD) and understand...
Oct 24, 20223 min read
MEFIB Index Can Have an Important Role in Clinical Management
https://pubmed.ncbi.nlm.nih.gov/35788349/ Abstract Background and aims: Magnetic resonance elastography (MRE) is an accurate biomarker of...
Jul 13, 20222 min read
Mayo Clinic Awarded FDA Grant for Biomarker Development
Rochester, MN, USA—Resoundant, Inc. announced that the Food and Drug Administration (FDA) has awarded Mayo Clinic $250,000 to further...
Nov 17, 20213 min read
MRE plus FIB-4 (MEFIB) versus FAST in detection of candidates for pharmacological treatment of NASH-
Abstract Background and aim: Nonalcoholic fatty liver disease (NAFLD) patients with significant hepatic fibrosis (stage ≥ 2) are at...
Sep 27, 20211 min read